{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:17:15Z","timestamp":1791101835990,"version":"4.1.0"},"reference-count":140,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.blre.2011.09.001","type":"journal-article","created":{"date-parts":[[2011,10,14]],"date-time":"2011-10-14T03:27:33Z","timestamp":1318562853000},"page":"279-290","source":"Crossref","is-referenced-by-count":56,"title":["Managing resistance in chronic myeloid leukemia"],"prefix":"10.1016","volume":"25","author":[{"given":"Sameek","family":"Roychowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2011.09.001_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.blre.2011.09.001_bb0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.286.8.895","article-title":"Chronic myelogenous leukemia","volume":"286","author":"Kalidas","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2011.09.001_bb0015","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198512053132301","article-title":"Evidence of a new chimeric bcr\/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome","volume":"313","author":"Stam","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.blre.2011.09.001_bb0025","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia (abstract)","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.blre.2011.09.001_bb0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.blre.2011.09.001_bb0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0040","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0045","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0050","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0055","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0060","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0705","first-page":"1126-","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009"},{"key":"10.1016\/j.blre.2011.09.001_bb0070","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0075","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.001_bb0080","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr\u2013Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0085","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.blre.2011.09.001_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR\u2013ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2011.09.001_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR\u2013ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.001_bb0100","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0105","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0115","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr\u2013Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0120","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0125","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR\u2013ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0135","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR\u2013ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0140","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0145","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR\u2013ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2011.09.001_bb0150","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR\u2013ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0155","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0160","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","article-title":"BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","volume":"68","author":"Stoklosa","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0165","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood-2002-10-3207","article-title":"p210 BCR\/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation","volume":"102","author":"Canitrot","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0170","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2008-07-172148","article-title":"BCR\u2013ABL promotes the frequency of mutagenic single-strand annealing DNA repair","volume":"114","author":"Fernandes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0175","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0180","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0185","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0190","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00228-009-0772-y","article-title":"CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity","volume":"66","author":"Green","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.blre.2011.09.001_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/bcmd.2002.0493","article-title":"Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571","volume":"28","author":"le Coutre","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2011.09.001_bb0200","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0205","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0006-2952(03)00469-6","article-title":"Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo","volume":"66","author":"Larghero","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.blre.2011.09.001_bb0210","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0215","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":"Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR\u2013ABL(+) leukemic cells to the abl inhibitor STI571","volume":"92","author":"Gambacorti-Passerini","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2011.09.001_bb0220","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2011.09.001_bb0225","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0230","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0235","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/leu.2010.16","article-title":"Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity","volume":"24","author":"Engler","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.001_bb0240","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-01-267013","article-title":"The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells","author":"Engler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0245","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E","article-title":"Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance","volume":"86","author":"Giles","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.09.001_bb0250","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0255","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/sj.leu.2404671","article-title":"Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels","volume":"21","author":"Widmer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.001_bb0260","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exphem.2005.03.014","article-title":"RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines","volume":"33","author":"Rumpold","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2011.09.001_bb0265","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.exphem.2009.02.006","article-title":"Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib","volume":"37","author":"Hatziieremia","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2011.09.001_bb0270","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0275","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.1996.14.1.196","article-title":"Significance of cytogenetic clonal evolution in chronic myelogenous leukemia","volume":"14","author":"Majlis","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0280","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cncr.22699","article-title":"Characterization of Ph-negative abnormal clones emerging during imatinib therapy","volume":"109","author":"Abruzzese","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.09.001_bb0285","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.07.030","article-title":"The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia","volume":"16","author":"Klemm","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2011.09.001_bb0290","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature04495","article-title":"Role of genomic instability and p53 in AID-induced c-myc-Igh translocations","volume":"440","author":"Ramiro","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.blre.2011.09.001_bb0295","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng.2007.35","article-title":"AID is required for germinal center-derived lymphomagenesis","volume":"40","author":"Pasqualucci","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2011.09.001_bb0300","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2009-03-210377","article-title":"SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations","volume":"115","author":"Nowak","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0305","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrg2626","article-title":"Sequencing technologies [mdash] the next generation","volume":"11","author":"Metzker","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.blre.2011.09.001_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0315","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood.V87.4.1539.bloodjournal8741539","article-title":"Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis","volume":"87","author":"Sirard","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0320","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0325","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0330","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1073\/pnas.0900189106","article-title":"Glycogen synthase kinase 3\u03b2 missplicing contributes to leukemia stem cell generation","volume":"106","author":"Abrahamsson","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2011.09.001_bb0335","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-[bgr]-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.blre.2011.09.001_bb0340","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.blre.2011.09.001_bb0345","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.leukres.2006.03.011","article-title":"Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon","volume":"30","author":"Breccia","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0350","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0355","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","article-title":"Chronic myeloid leukemia stem cells","volume":"26","author":"Kavalerchik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0360","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2011.09.001_bb0365","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr\u2013abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0370","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR\u2013ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0375","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR\u2013ABL inhibitors","volume":"8","author":"Grosso","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2011.09.001_bb0380","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR\u2013ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0385","first-page":"3589","article-title":"Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells","volume":"56","author":"Danhauser-Riedl","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0390","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.leu.2401429","article-title":"Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth","volume":"13","author":"Roginskaya","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.001_bb0395","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR\u2013ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2011.09.001_bb0400","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR\u2013ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2011.09.001_bb0405","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr\u2013Abl","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2011.09.001_bb0410","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0415","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V94.7.2452.419k23_2452_2460","article-title":"ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia","volume":"94","author":"Asimakopoulos","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0420","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0425","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0430","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance","volume":"27","author":"Zhang","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0435","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0440","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0445","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0450","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0455","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0460","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2011.09.001_bb0465","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR\u2013ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0470","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.09.001_bb0475","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.001_bb0480","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.13529","article-title":"The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up","volume":"94","author":"Palandri","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.09.001_bb0485","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0490","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0495","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0500","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.001_bb0505","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2011.09.001_bb0510","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr\u2013Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2011.09.001_bb0515","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0520","first-page":"2201-","volume":"114","author":"Nicolini","year":"2009"},{"key":"10.1016\/j.blre.2011.09.001_bb0525","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0530","first-page":"1130-","article-title":"Response and outcomes to nilotinib at 24months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR\u2013ABL mutations","volume":"114","author":"Radich","year":"2009"},{"key":"10.1016\/j.blre.2011.09.001_bb0535","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"key":"10.1016\/j.blre.2011.09.001_bb0540","first-page":"3229-","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 Study","volume":"112","author":"le Coutre","year":"2008"},{"key":"10.1016\/j.blre.2011.09.001_bb0545","first-page":"1025-","article-title":"Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib","volume":"110","author":"Giles","year":"2007"},{"key":"10.1016\/j.blre.2011.09.001_bb0550","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR\u2013ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0555","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR\u2013ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0560","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0565","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","article-title":"Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity","volume":"44","author":"Boschelli","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2011.09.001_bb0570","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2011.09.001_bb0575","first-page":"1098-","article-title":"Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib","volume":"112","author":"Cortes","year":"2008"},{"key":"10.1016\/j.blre.2011.09.001_bb0710","first-page":"1101-","article-title":"Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ all","volume":"112","author":"Passerini","year":"2008"},{"key":"10.1016\/j.blre.2011.09.001_bb0585","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bmcl.2005.11.042","article-title":"Design and synthesis of 3-substituted benzamide derivatives as Bcr\u2013Abl kinase inhibitors","volume":"16","author":"Asaki","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.blre.2011.09.001_bb0590","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr\u2013Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0595","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","article-title":"Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.09.001_bb0600","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood-2004-05-1851","article-title":"Inhibition of wild-type and mutant Bcr\u2013Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML","volume":"104","author":"O'Hare","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0605","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR\u2013ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2011.09.001_bb0610","first-page":"643-","article-title":"A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations","volume":"114","author":"Cortes","year":"2009"},{"key":"10.1016\/j.blre.2011.09.001_bb0615","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/leu.2010.15","article-title":"Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias","volume":"24","author":"Moore","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.001_bb0620","first-page":"864-","article-title":"Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia","volume":"114","author":"Cortes-Franco","year":"2009"},{"key":"10.1016\/j.blre.2011.09.001_bb0625","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/jm800984v","article-title":"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity\u2020","volume":"52","author":"Howard","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2011.09.001_bb0630","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-03-211466","article-title":"Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR\u2013ABL positive leukemic cells","author":"Tanaka","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0635","first-page":"904-","article-title":"A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies","volume":"110","author":"Ravandi","year":"2007"},{"key":"10.1016\/j.blre.2011.09.001_bb0640","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.09.001_bb0645","first-page":"861-","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors \u2014 results of a multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009"},{"key":"10.1016\/j.blre.2011.09.001_bb0650","first-page":"644-","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr\u2013Abl T315I mutation\u2014results of an ongoing multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009"},{"key":"10.1016\/j.blre.2011.09.001_bb0655","first-page":"463-","article-title":"DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR\u2013ABL T315I in vitro and in a CML mouse model","volume":"110","author":"Van Etten","year":"2007"},{"key":"10.1016\/j.blre.2011.09.001_bb0660","first-page":"576-","article-title":"Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR\u2013ABL T315I","volume":"112","author":"Van Etten","year":"2008"},{"key":"10.1016\/j.blre.2011.09.001_bb0665","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-\u03b1 therapy","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2011.09.001_bb0670","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-{alpha} is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.09.001_bb0675","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.001_bb0680","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European Leukemianet Management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2011.09.001_bb0685","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR\u2013ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.001_bb0690","first-page":"469-","article-title":"A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors","volume":"110","author":"Kantarjian","year":"2007"},{"key":"10.1016\/j.blre.2011.09.001_bb0695","first-page":"2967-","article-title":"A phase I dose escalation study of kw-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed\/Refractory AML, ALL and MDS or Resistant\/Intolerant CML","volume":"112","author":"Cortes","year":"2008"},{"key":"10.1016\/j.blre.2011.09.001_bb0700","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR\u2013ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1100066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X1100066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T18:01:59Z","timestamp":1713031319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X1100066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":140,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0268960X1100066X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2011.09.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}